GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ViroGates AS (OCSE:VIRO) » Definitions » Float Percentage Of Total Shares Outstanding

ViroGates AS (OCSE:VIRO) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 19, 2025)


View and export this data going back to 2018. Start your Free Trial

What is ViroGates AS Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ViroGates AS's float shares is 0.00 Mil. ViroGates AS's total shares outstanding is 7.73 Mil. ViroGates AS's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ViroGates AS's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ViroGates AS's Institutional Ownership is 0.32%.


ViroGates AS Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

ViroGates AS's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/7.73
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViroGates AS Business Description

Industry
Traded in Other Exchanges
N/A
Address
Banevaenget 13, Birkerod, DNK, DK-3460
ViroGates AS is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.

ViroGates AS Headlines

No Headlines